PRCT — PROCEPT BioRobotics Share Price
Last trade - 00:00- $1.04bn
- $863.32m
- $308.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.06 | ||
| Price to Tang. Book | 3.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.51% | ||
| Return on Equity | -30.24% | ||
| Operating Margin | -33.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 34.47 | 75.01 | 136.19 | 224.5 | 308.05 | 395.41 | 476.86 | 109.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). It designed Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that is independent of prostate size and shape and delivers resection independent of surgeon experience. It manufactures the robotic systems, the single-use disposable handpiece, integrated scope and other accessories at its facility in San Jose, California. Each robotic system is shipped to its customers with a third-party manufactured ultrasound system and probe.
Directors
- Frederic Moll CHM
- Reza Zadno PRE
- Kevin Waters CFO
- Surag Mantri SVP
- Matthew Salkeld VPR
- Taylor Harris DRC (45)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 29th, 2021
- Public Since
- September 15th, 2021
- No. of Shareholders
- 218
- No. of Employees
- 888
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 57,273,659
- Address
- 150 Baytech Drive, SAN JOSE, 95134
- Web
- https://www.procept-biorobotics.com/
- Phone
- +1 6502329832
- Auditors
- PricewaterhouseCoopers LLP
Latest News for PRCT
Upcoming Events for PRCT
Q3 2026 PROCEPT BioRobotics Corporation Earnings Release
Q3 2026 PROCEPT BioRobotics Corporation Earnings Call
Q4 2026 Procept Biorobotics Corp Earnings Release
Similar to PRCT
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anbio Biotechnology
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
FAQ
As of Today at 04:48 UTC, shares in PROCEPT BioRobotics are trading at $18.15. This share price information is delayed by 15 minutes.
Shares in PROCEPT BioRobotics last closed at $18.15 and the price had moved by -46.24% over the past 365 days. In terms of relative price strength the PROCEPT BioRobotics share price has underperformed the S&P500 Index by -53.98% over the past year.
The overall consensus recommendation for PROCEPT BioRobotics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePROCEPT BioRobotics does not currently pay a dividend.
PROCEPT BioRobotics does not currently pay a dividend.
PROCEPT BioRobotics does not currently pay a dividend.
To buy shares in PROCEPT BioRobotics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $18.15, shares in PROCEPT BioRobotics had a market capitalisation of $1.04bn.
Here are the trading details for PROCEPT BioRobotics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: PRCT
Based on an overall assessment of its quality, value and momentum PROCEPT BioRobotics is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in PROCEPT BioRobotics is $24.57. That is 35.37% above the last closing price of $18.15.
Analysts covering PROCEPT BioRobotics currently have a consensus Earnings Per Share (EPS) forecast of -$1.67 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PROCEPT BioRobotics. Over the past six months, its share price has underperformed the S&P500 Index by -33.72%.
As of the last closing price of $18.15, shares in PROCEPT BioRobotics were trading -24.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The PROCEPT BioRobotics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
PROCEPT BioRobotics' management team is headed by:
- Frederic Moll - CHM
- Reza Zadno - PRE
- Kevin Waters - CFO
- Surag Mantri - SVP
- Matthew Salkeld - VPR
- Taylor Harris - DRC